Industry Overview

Influenza diagnostic market was valued at $1.5 billion in 2025 and is projected to reach $2.9 billion by 2035, growing at a CAGR of 6.8% during the forecast Period (2026-2035). The market is growing due to rising influenza prevalence, technological advancements in rapid and molecular tests, and government initiatives for surveillance and awareness. Other key factors include the demand for point-of-care testing, the aging population's susceptibility to the flu, and the importance of accurate diagnostics for distinguishing flu from other respiratory illnesses. Challenges include the cost of some advanced tests and the need for better lab infrastructure in some regions.

Market Dynamics 

Rising Global Burden of Influenza and Expansion of Respiratory Disease Surveillance

Seasonal influenza continues to affect millions each year, creating predictable surges in clinical testing demand. However, since the COVID-19 pandemic, global health systems have strengthened respiratory-virus surveillance programs, which now require year-round testing rather than only seasonal diagnostics. National public-health agencies are increasingly integrating influenza into multiplex respiratory panels and expanding sentinel surveillance sites. This ongoing shift from episodic to continuous monitoring significantly boosts testing volumes across hospitals, diagnostic laboratories, and public-health facilities, driving sustained market growth.

Growing Adoption of Rapid Molecular Assays and Multiplex Testing Technologies

Technological advancements are strongly accelerating the market, especially rapid molecular platforms that offer superior sensitivity and faster turnaround times compared to traditional RIDTs. Multiplex assays capable of simultaneously detecting influenza A/B, RSV, and SARS-CoV-2 are becoming a clinical standard because they improve diagnostic accuracy and streamline treatment decisions during overlapping respiratory seasons. Manufacturers are launching compact point-of-care molecular systems with near-PCR accuracy, enabling decentralized testing across clinics, pharmacies, and urgent-care centers. This shift toward advanced, high-performance diagnostics is one of the strongest drivers of market expansion.

Increased Decentralization of Testing Toward Point-of-Care And Home-Based Settings

Global healthcare delivery is rapidly moving toward decentralized and patient-centric models, creating strong demand for easy-to-use rapid antigen tests and portable molecular devices. Pharmacies, retail clinics, and at-home testing channels are gaining prominence, supported by evolving reimbursement policies, telehealth integration, and consumer preference for quick diagnosis without hospital visits. This decentralization reduces testing backlog in clinical laboratories and increases overall testing frequency, enabling greater accessibility in both developed and emerging markets. As a result, point-of-care (POC) diagnostics are becoming a central growth engine for the global influenza diagnostic market.

Market Segmentation

• Based on the test type, the market is segmented into molecular diagnostic assays and traditional diagnostic tests.
• Based on the end-users, the market is segmented into hospitals & diagnostic laboratories, research & academic institutes, and contract research organizations.

Molecular Diagnostic Assays  Segment to Grow at a Considerable Market Share

Among all the segments in the Global Influenza Diagnostic Market, molecular diagnostic assays emerge as the largest and leading segment, driven primarily by its superior accuracy, rapid turnaround time, and ability to detect influenza strains with high sensitivity. Within this category, RT-PCR technology remains the gold standard due to its reliability in identifying viral RNA, especially during seasonal and pandemic outbreaks. The growing global emphasis on precision diagnostics, coupled with continuous advancements in molecular platforms such as LAMP, NASBA, and SAMBA, further strengthens the dominance of this segment. Additionally, increasing adoption across hospitals, diagnostic centers, and research institutes, along with rising investment in molecular testing infrastructure, solidifies its position as the key revenue generator and the leading driver of market expansion worldwide.

Hospitals & Diagnostic Centers: A Key Segment in Market Growth

Among all end-user segments in the global influenza diagnostics market, hospitals & diagnostic centers represent the dominant and fastest-growing segment, contributing the largest share to market expansion. This leadership position is driven by the high patient influx, advanced testing infrastructure, and the urgent need for rapid diagnosis during seasonal influenza outbreaks and pandemic-like situations. Hospitals and diagnostic labs are the primary points of care where patients with influenza-like illness first seek medical attention, leading to a significantly higher volume of influenza testing compared to research institutes or CROs. Additionally, these facilities have greater adoption rates for advanced molecular diagnostic assays such as RT-PCR, rapid molecular tests, and antigen-based point-of-care kits, ensuring accurate and timely detection of influenza strains. The growth of this segment is further supported by rising global healthcare expenditure, government-funded influenza surveillance programs, and the expansion of diagnostic networks in both developed and developing regions. Hospitals also benefit from improved accessibility to novel diagnostic platforms, including automated PCR systems and multiplex panels capable of detecting influenza A, influenza B, and emerging variants. Moreover, the increasing burden of comorbidities such as COPD, asthma, and cardiovascular diseases among influenza patients drives physicians to rely on hospital-based diagnostic procedures for effective clinical management. Overall, Hospitals & Diagnostic Centers remain central to driving market growth due to their crucial role in disease detection, outbreak control, and patient care delivery.

Regional Outlook

the global influenza diagnostic market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Region to Hold a Substantial Growth Rate

In North America, the US dominates the global influenza diagnostic market, holding the largest market share due to its combination of advanced healthcare infrastructure, high per-capita testing rates, and robust public health policies. The country’s leadership in diagnostic technology innovation, particularly in molecular assays and rapid point-of-care tests, has strengthened its position. Key players such as Roche, Abbott, Thermo Fisher (Cepheid), Quidel/Ortho, and Becton Dickinson have a significant presence in the US, leveraging strong distribution networks, regulatory approvals, and partnerships with hospitals, clinics, and public health agencies. Additionally, the US benefits from consistent government funding for influenza surveillance, pandemic preparedness programs, and stockpiling of diagnostic kits, ensuring a stable baseline demand even outside peak influenza seasons. The high incidence of seasonal influenza, coupled with increasing awareness of respiratory disease management post-COVID-19, has further accelerated the adoption of rapid, accurate diagnostics. Advanced laboratory infrastructure and integration of multiplex testing in hospitals and large diagnostic centers support continuous market growth. Emerging trends such as point-of-care molecular testing and at-home influenza kits are rapidly gaining traction in the US, reinforcing its position as the global market leader. Collectively, these factors make the US the single most influential country in shaping the trajectory of the global influenza diagnostic market.

Market Players Outlook

The major companies operating in the global influenza diagnostic market include Abbott Laboratories, Becton, Dickinson and Company (BD), F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., QuidelOrtho Corp., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.

Recent Development

• In September 2025, QuidelOrtho launched the QUICKVUE Influenza + SARS Test, expanding its QUICKVUE portfolio. This CLIA-waived, 510(k)–cleared immunoassay is designed for professional use in various healthcare settings, providing rapid detection and differentiation of influenza A, influenza B, and SARS-CoV-2 from a single patient sample. Results are available in as fast as 10 minutes, aiding clinicians in distinguishing COVID-19 from seasonal flu. Key features include triple detection capability, fast results, professional use applicability, an efficient workflow with easy nasal swab collection, and affordability.
• In September 2025, QuidelOrtho Corp introduced the QUICKVUE Influenza + SARS Test, a rapid immunoassay that detects influenza A, influenza B, and SARS-CoV-2 antigens from a single nasal swab sample, providing results in as fast as 10 minutes. The CLIA-waived, 510(k)-cleared test is designed for use in various clinical settings, including physician offices and urgent care centers. It helps clinicians differentiate between COVID-19 and seasonal flu symptoms. This test expands QuidelOrtho’s respiratory testing portfolio, which already includes the SOFIA 2 Flu + SARS Antigen FIA, and is available in the US for professional use only.
• In January 2025, ARUP launched a new assay for the detection and subtyping of influenza A (H5) virus, which will assist in evaluating individuals potentially exposed to highly pathogenic avian influenza A (H5N1). Following an outbreak identified in early 2024 in poultry and dairy cattle across several states, the CDC reports 66 confirmed human cases of bird flu in the US since April 2024, including one hospitalization in Louisiana.

The Report Covers

• Market value data analysis for 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global influenza diagnostic market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.